Ser446
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser446  -  DUSP16 (human)

Site Information
TNKLCQFsPVQELSE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 449606

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 4 ) , mass spectrometry ( 1 , 2 ) , mutation of modification site ( 3 , 4 ) , phospho-antibody ( 3 )
Disease tissue studied:
luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:
breast ( 1 ) , COS (fibroblast) ( 3 , 4 ) , HeLa (cervical) ( 2 )

Upstream Regulation
Putative in vivo kinases:
ERK2 (human) ( 4 )
Treatments:
phorbol_ester ( 3 , 4 )

Downstream Regulation
Effects of modification on DUSP16:
protein stabilization ( 3 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Katagiri C, et al. (2005) Phosphorylation of Ser-446 determines stability of MKP-7. J Biol Chem 280, 14716-22
15689616   Curated Info

4

Masuda K, Shima H, Katagiri C, Kikuchi K (2003) Activation of ERK induces phosphorylation of MAPK phosphatase-7, a JNK specific phosphatase, at Ser-446. J Biol Chem 278, 32448-56
12794087   Curated Info